Clinical Trial Update: Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DNK333 (25 mg and 100 mg bid) in women with diarrhea-predominant irritable bowel syndrome reported efficacy, safety and tolerability re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• DNK333

Snippet

Sponsor: Novartis | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED